Key result
Acute administration of losartan, but not enalapril, improved plasma fibrinolytic parameters in heart failure patients.
Why the study?
Does acute administration of losartan compared to enalapril improve plasma fibrinolytic parameters in patients with moderately severe chronic heart failure?
RCT (n=20)
Single-blind
crossover
Does acute administration of losartan compared to enalapril improve plasma fibrinolytic parameters in patients with moderately severe chronic heart failure?
Answers are grounded in this paper and cite their sources.
Acute AT1 receptor antagonism with losartan significantly improves plasma fibrinolytic parameters to a greater extent than ACE inhibition with enalapril in patients with heart failure.
BACKGROUND: Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibrinolytic parameters. The aim of the present study was to determine whether acute ACE inhibition and angiotensin II type 1 (AT1) receptor antagonism have similar effects in patients with heart failure. METHODS AND RESULTS: Twenty patients with moderately severe chronic heart failure received enalapril 10 mg and losartan 50 mg on 2 separate occasions in a single-blind, randomized, crossover design. Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity were measured at baseline and 6 hours after the dose. Acute administration of losartan but not of enalapril reduced plasma t-PA (11%; P=0.003) and PAI-1 (38%; P<0.001) antigen concentrations, which was associated with increases in t-PA (29%; P=0.03) and decreases in PAI-1 (48%; P=0.01) activity. Changes in plasma fibrinolytic parameters were more marked during losartan treatment (P<0.02), with a 3-fold greater reduction in plasma PAI-1 antigen concentrations (P<0.05). CONCLUSIONS: Acute AT1 antagonism in patients with heart failure is associated with a significant improvement in plasma fibrinolytic parameters that is greater than during ACE inhibition. These beneficial effects of AT1 antagonism and ACE inhibition would therefore appear to be mediated principally through suppression of angiotensin II.
No takes yet. Share an insight, caveat, or question.
Goodfield et al. (1999) conducted an RCT in moderately severe chronic heart failure (n=20). Losartan vs. Enalapril 10 mg was evaluated on Plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen and activity (p=<0.02). Acute administration of losartan, but not enalapril, improved plasma fibrinolytic parameters in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: